BiotechTube

APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Conditions

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Trial Timeline

Mar 1, 2014 → Apr 1, 2019

NCT ID
NCT02098343

About APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) is a phase 1/2 stage product being developed by Aprea Therapeutics for Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53. The current trial status is completed. This product is registered under clinical trial identifier NCT02098343. Target conditions include Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02098343Phase 1/2Completed

Competing Products

20 competing products in Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
ASP1650Astellas PharmaPhase 2
52
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
Farletuzumab + PlaceboEisaiPhase 2
52
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
52
OLAPARIBAstraZenecaPhase 2
52
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
41
cediranib and olaparibAstraZenecaPhase 2
52
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
52
OLAPARIB + PLACEBOAstraZenecaPhase 3
77
ZD4054 Zibotentan + Paclitaxel + Carboplatin + PlaceboAstraZenecaPhase 2
52
OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
77
Olaparib 300mg tablets + Placebo to match olaparib 300mgAstraZenecaPhase 3
77
TILT-123 + pembrolizumab + pegylated liposomal doxorubicinMerckPhase 1/2
41
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]MerckPhase 2
52
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
77
IBI363+IBI305Innovent BiologicsPhase 2
51

Other Products from Aprea Therapeutics

APR-246 + azacitidine + AzacitidinePhase 3
69
APR-246Phase 2
44
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 2
44
APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RTPhase 1/2
33
APR-246 + AzacitidinePhase 1/2
33